August 21, 2023 10:00 AM EDTUpdated 11:25 AM
People

The End­points Slack In­ter­view: NewLim­it's Ja­cob Kim­mel brings an­ti-ag­ing back to re­al­i­ty

Andrew Dunn

Senior Biopharma Correspondent

In a field full of ec­centrics, Ja­cob Kim­mel may stand out most for his nor­mal­i­ty.

Kim­mel is a lead­ing an­ti-ag­ing re­searcher who isn’t try­ing to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Take­da to pay $200M for rights to ane­mia drug from Keros

Janux soars on ear­ly prostate can­cer da­ta that could chal­lenge No­var­tis' Plu­vic­to

Rev­o­lu­tion sells $600M in shares on back of RAS in­hibitor port­fo­lio up­dates

Roche teams up with Chica­go au­toim­mune biotech COUR Phar­ma­ceu­ti­cals

Gilead makes an­oth­er ADC move, ink­ing up to $415M pact with Tubu­lis

Ipsen se­cures rights to pre­clin­i­cal T cell en­gager in $610M pact with French biotech

A service from the Financial Times